BiotechTube

Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Folinate

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Resectable Colon Cancer

Conditions

Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer

Trial Timeline

Mar 15, 2026 → Mar 15, 2031

NCT ID
NCT07412613

About Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Folinate

Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Folinate is a phase 3 stage product being developed by Akeso for Resectable Colon Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07412613. Target conditions include Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer.

What happened to similar drugs?

1 of 20 similar drugs in Resectable Colon Cancer were approved

Approved (1) Terminated (0) Active (19)
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄CamrelizumabJiangsu Hengrui MedicinePhase 3
🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07412613Phase 3Recruiting

Competing Products

20 competing products in Resectable Colon Cancer

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
LenvatinibEisaiPhase 2
35
LenvatinibEisaiPhase 1
29
LenvatinibEisaiPhase 1/2
36
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
42
CamrelizumabJiangsu Hengrui MedicinePhase 3
47
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
40